DOCS:NYE-Doximity Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 58.51

Change

0.00 (0.00)%

Market Cap

USD 13.23B

Volume

2.28M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

N/A

USD 13.78B
WEAV Weave Communications Inc

N/A

USD 0.83B
AMWL American Well Corp

N/A

USD 0.12B
CTEV Claritev Corporation

N/A

N/A
EVH Evolent Health Inc

N/A

N/A
PHR Phreesia Inc

N/A

N/A
TDOC Teladoc Inc

N/A

N/A
VEEV Veeva Systems Inc Class A

N/A

N/A
FOXO FOXO Technologies Inc.

N/A

N/A

ETFs Containing DOCS

EDOC:LSE Global X Telemedicine & D.. 6.15 % 0.00 %

N/A

USD 4.95M
EDOG:LSE Global X Telemedicine & D.. 6.15 % 0.00 %

N/A

USD 0.33M
DDOC:F Global X Telemedicine & D.. 5.22 % 0.00 %

N/A

N/A
EDOC:SW Global X Telemedicine & D.. 4.76 % 0.00 %

N/A

N/A
EDOC:AU 4.31 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 3.83 % 0.00 %

N/A

USD 2.40M
FDOC:LSE 3.79 % 0.00 %

N/A

N/A
LSEQ Harbor ETF Trust 1.79 % 0.00 %

N/A

USD 0.02B
FYC First Trust Small Cap Gro.. 0.82 % 0.70 %

N/A

USD 0.41B
FYX First Trust Small Cap Cor.. 0.41 % 0.63 %

N/A

USD 0.85B
BFOR Barron's 400 ETF 0.00 % 0.65 %

N/A

USD 0.14B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
FXH First Trust Health Care A.. 0.00 % 0.63 %

N/A

USD 1.01B
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

N/A

USD 0.43B
HDGE:CA Accelerate Absolute Retur.. 0.00 % 0.00 %

N/A

CAD 0.05B
XITK SPDR® FactSet Innovative.. 0.00 % 0.45 %

N/A

USD 0.09B
QBTL:CA AGFiQ US Market Neutral A.. 0.00 % 0.00 %

N/A

CAD 0.26B
SMDY 0.00 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.04B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
JFWD 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.59% 78% C+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.59% 78% C+ 88% B+
Trailing 12 Months  
Capital Gain 117.43% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 117.43% 100% F 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.90% 70% C- 42% F
Dividend Return 1.90% 60% D- 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.53% 60% D- 18% F
Risk Adjusted Return 3.77% 60% D- 24% F
Market Capitalization 13.23B 75% C 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.